Key result
Radiofrequency ablation successfully treats drug-resistant SVT in an infant, allowing complete medication discontinuation.
Case Report (n=1)
No
Radiofrequency ablation can be a viable and effective intervention for life-threatening, drug-resistant SVT in infants, potentially rendering subsequent recurrences responsive to standard medical therapy.
May support ablation in refractory infant SVT; extends sparse case data but leaves generalizability open.
Supraventricular tachycardia (SVT) in infants may be resistant to multiple medications and cause life-threatening symptoms. Despite the known risks, catheter ablation may be necessary in rare cases. We present a 4-month-old 4.5 kg infant who presented with SVT that was resistant to all antiarrhythmic medications, including a combination of propafenone, amiodarone and propranolol at maximal doses. The infant underwent successful radiofrequency ablation of a posteroseptal accessory pathway. Despite later recurrence, medical therapy with propafenone and propranolol at standard doses resulted in complete control of the tachycardia until one year of age, when all medications were stopped without further recurrences.
No takes yet. Share an insight, caveat, or question.
Papagiannis et al. (2010) conducted a case report in Supraventricular tachycardia (n=1). Radiofrequency ablation was evaluated on Termination of tachycardia. Radiofrequency ablation successfully treated life-threatening, drug-resistant supraventricular tachycardia in a 4-month-old infant, allowing for complete discontinuation of medications by one year of age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: